MOTS-c testing round-up: what our latest samples measured
What the published research on MOTS-c does and does not establish.
The Peptide Institute Testing Desk··Updated ·13 min read
MOTS-c is a mitochondrial-derived peptide with a development status of "preclinical / early human trials". The Institute rates the strength of its published evidence as emerging. A mitochondrial-encoded peptide studied in metabolism and exercise-physiology research.
This report covers the MOTS-c samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
The two halves of the Wolverine stack just won a big vote from an FDA advisory committee. Here is what happened, why it matters, and the White House review that could come next.
23 samples, 12 sellers, one compound with almost no human evidence behind it. Measured purity ranged from 61% to 98.9%.
Institute Investigation
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
